Compare Bristol-Myers Squibb Co (BMY) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Bristol-Myers Squibb Co trades at $58.54 (market cap $116.30B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.91. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| BMY | YMAG | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $15.98 |
52-Week Low | $42.60 | $11.00 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
YMAG trades at $11.70, down 0.93% on the day, with technical indicators showing a neutral overall signal. The ETF has demonstrated consistent weekly dividend distributions throughout 2026, with payouts ranging from $0.07 to $0.40 per share. Recent news highlights YMAG's strategy of bundling Magnificent Seven exposure through option income ETFs, though some analysts express concerns about NAV decay and limited upside potential.
The outlook for YMAG hinges on its ability to generate sustainable option income while managing the trade-off between yield and capital appreciation. Key risks include high expense ratios, underperformance during strong bull markets, and dependence on volatility premiums. Institutional interest appears mixed, with the fund's appeal concentrated among income-focused investors seeking Magnificent Seven exposure with enhanced yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
